308 related articles for article (PubMed ID: 34570179)
21. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
22. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K
Exp Hematol Oncol; 2022 May; 11(1):32. PubMed ID: 35610628
[TBL] [Abstract][Full Text] [Related]
23. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients.
Lee WH; Lin CC; Tsai CH; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2022 Dec; 97(12):1589-1598. PubMed ID: 36109871
[TBL] [Abstract][Full Text] [Related]
24. Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.
Bhai P; Chin-Yee B; Pope V; Cheong I; Matyashin M; Levy MA; Foroutan A; Stuart A; Hsia CC; Lin H; Sadikovic B; Chin-Yee I
Curr Oncol; 2022 Sep; 29(10):7209-7217. PubMed ID: 36290845
[No Abstract] [Full Text] [Related]
25. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
26. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
27. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
Kar SA; Jankowska A; Makishima H; Visconte V; Jerez A; Sugimoto Y; Muramatsu H; Traina F; Afable M; Guinta K; Tiu RV; Przychodzen B; Sakaguchi H; Kojima S; Sekeres MA; List AF; McDevitt MA; Maciejewski JP
Haematologica; 2013 Jan; 98(1):107-13. PubMed ID: 22773603
[TBL] [Abstract][Full Text] [Related]
28. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
Shih AH; Chung SS; Dolezal EK; Zhang SJ; Abdel-Wahab OI; Park CY; Nimer SD; Levine RL; Klimek VM
Haematologica; 2013 Jun; 98(6):908-12. PubMed ID: 23349305
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
31. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract][Full Text] [Related]
32. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
Hochman MJ; Savani BN; Jain T
EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
[TBL] [Abstract][Full Text] [Related]
33. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of clonal hematopoiesis in persons aged ≥80 years.
Rossi M; Meggendorfer M; Zampini M; Tettamanti M; Riva E; Travaglino E; Bersanelli M; Mandelli S; Antonella Galbussera A; Mosca E; Saba E; Chiereghin C; Manes N; Milanesi C; Ubezio M; Morabito L; Peano C; Soldà G; Asselta R; Duga S; Selmi C; De Santis M; Malik K; Maggioni G; Bicchieri M; Campagna A; Tentori CA; Russo A; Civilini E; Allavena P; Piazza R; Corrao G; Sala C; Termanini A; Giordano L; Detoma P; Malabaila A; Sala L; Rosso S; Zanetti R; Saitta C; Riva E; Condorelli G; Passamonti F; Santoro A; Sole F; Platzbecker U; Fenaux P; Bolli N; Castellani G; Kern W; Vassiliou GS; Haferlach T; Lucca U; Della Porta MG
Blood; 2021 Nov; 138(21):2093-2105. PubMed ID: 34125889
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
36. ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
West RR; Calvo KR; Embree LJ; Wang W; Tuschong LM; Bauer TR; Tillo D; Lack J; Droll S; Hsu AP; Holland SM; Hickstein DD
Blood Adv; 2022 Feb; 6(3):793-807. PubMed ID: 34529785
[TBL] [Abstract][Full Text] [Related]
37. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.
Yu K; Deuitch N; Merguerian M; Cunningham L; Davis J; Bresciani E; Diemer J; Andrews E; Young A; Donovan F; Sood R; Craft K; Chong S; Chandrasekharappa S; Mullikin J; Liu PP
Blood Adv; 2024 Jan; 8(2):497-511. PubMed ID: 38019014
[TBL] [Abstract][Full Text] [Related]
38. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
39. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
Lee WH; Lin CC; Wang YH; Yao CY; Kuo YY; Tseng MH; Peng YL; Hsu CA; Sun HI; Chuang YK; Hsu CL; Tien FM; Tsai CH; Chou WC; Hou HA; Tien HF
Hematol Oncol; 2023 Aug; 41(3):463-473. PubMed ID: 36420747
[TBL] [Abstract][Full Text] [Related]
40. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
